Sign In
Buy SPRB
$42.83
-0.540 (-1.25%)
At Close: Jul 31, 2026
ADVANZ PHARMA (OTCMKTS:CXRXF) versus Spruce Biosciences (NASDAQ:SPRB) Head-To-Head Contrast
02:42am, Friday, 24'th Oct 2025
ADVANZ PHARMA (OTCMKTS:CXRXF - Get Free Report) and Spruce Biosciences (NASDAQ: SPRB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the t
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 15'th Oct 2025
Does Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)
10:38am, Tuesday, 07'th Oct 2025
Spruce Biosciences received FDA Breakthrough Therapy Designation for TA-ERT in treating San Filippo Syndrome Type B [MPS IIIB]. BTD enables potential rolling BLA submission, Priority Review, and Accel
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.
09:44am, Tuesday, 07'th Oct 2025
The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.
Spruce Biosciences shares pop after FDA grants Breakthrough Therapy Designation for rare disease treatment
01:07pm, Monday, 06'th Oct 2025
Spruce Biosciences (NASDAQ:SPRB) shares surged more than 390% to around $43 following news that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its tr
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
07:00am, Monday, 15'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
04:05pm, Thursday, 14'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Announces Reverse Stock Split
04:01pm, Thursday, 24'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
10:31am, Tuesday, 22'nd Jul 2025
Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANC
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
08:00am, Thursday, 12'th Jun 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
04:01pm, Tuesday, 06'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological di
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
05:27pm, Tuesday, 15'th Apr 2025
Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medic
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
01:06pm, Friday, 13'th Dec 2024
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
